SOPHiA GENETICS Releases Preliminary Financial Results and Transitions Leadership for Future Growth

SOPHiA GENETICS Announces Preliminary Financial Results and Leadership Changes

On January 12, 2026, SOPHiA GENETICS (NASDAQ: SOPH), a pioneering force in AI-powered precision medicine, disclosed its preliminary, unaudited financial outcomes for the fourth quarter and the full year of 2025. The announcement also included a forward-looking financial outlook for 2026, alongside an important executive transition plan.

Strong Q4 Performance

The company concluded 2025 with impressive results in the fourth quarter, reporting a revenue of at least $21 million. This signifies a year-over-year increase of approximately 20%. This robust performance was supported by the completion of more than 105,000 analyses through its innovative platform, SOPHiA DDM™, marking a significant 16% growth compared to the previous year.

Full Year Overview

For the entire year of 2025, SOPHiA GENETICS recorded a revenue of about $77 million, which reflects an approximately 18% growth from 2024. The company set a new benchmark by conducting over 391,000 analyses on the SOPHiA DDM™ platform in one year.

Chief Executive Officer Jurgi Camblong expressed optimism about the company's trajectory, stating, "2025 was a tremendous year for SOPHiA GENETICS as we reaccelerated revenue growth and materially exceeded our new business bookings target, setting the stage for future expansion." He emphasized the potential growth drivers for 2026, which include their advanced Liquid Biopsy application, MSK-ACCESS®, and a renewed focus on the BioPharma sector.

Financial Projections for 2026

Looking ahead, SOPHiA GENETICS anticipates revenue for the fiscal year 2026 to be between $92 million and $94 million, indicating an approximate growth rate of 20% to 22% year-over-year. However, the company also expects an adjusted EBITDA loss ranging from $29 million to $32 million as it continues to invest in growth opportunities.

Leadership Transition

A significant part of the announcements included a leadership transition plan, where Ross Muken will step into the role of Chief Executive Officer effective July 1, 2026. Muken has been integral to SOPHiA's operations since he joined the company in February 2021 as Chief Financial Officer. His capabilities were recognized leading to his promotion as joint CFO and Chief Operating Officer in March 2023, and later to President in May 2024. In his time, he has been pivotal in reshaping the commercial strategy and propelling business growth.

Jurgi Camblong, the company’s co-founder, will assume the role of Executive Chairman, allowing him to focus on strategic initiatives. Dr. Tomer Berkovitz, a Board member, stated that the executive changes are part of a long-term succession plan, acknowledging Jurgi’s significant contributions to the company’s achievements.

Looking Forward

With the departure of Jurgi, whose leadership has carved SOPHiA GENETICS into a leading entity in the AI-driven precision medicine landscape, the company's future under Muken is highly anticipated. Muken stated, "I am deeply honored to succeed Jurgi as CEO and look forward to continuing our partnership as he transitions to Executive Chairman," highlighting the collaborative ethos cultivated within the company.

Kevin Puylaert will be stepping up as the Chief Sales Officer from January 2026, further reinforcing the leadership team as SOPHiA GENETICS aims for a transformative year ahead.

Conclusion

As the company progresses into 2026, it is positioned for continued success, with strategic initiatives aimed at expanding its influence in the evolving landscape of personalized healthcare. Analysts and stakeholders will be keenly awaiting the finalized financials scheduled for release during the first earnings call of 2026, set for March 3, 2026. As SOPHiA GENETICS continues its commitment to democratizing data-driven medicine globally, all eyes will be on the developments that unfold from this strategic leadership transition.